Retatrutide, a new peptide currently under study, allows for major and rapid weight loss by acting on satiety signals.

noli's read

This assertion is based on very solid clinical data, notably a phase 2 randomized controlled trial (RCT) published in the New England Journal of Medicine in 2023. Researchers observed a spectacular average weight loss of up to 24.2% over 48 weeks for the maximum dose. This innovative peptide acts by mimicking three different hormones to optimize the sensation of satiety and the body’s energy management. While the creator mentions phase 3, it is indeed the published results from phase 2 that currently confirm this record efficacy, as phase 3 studies are still being deployed. Transient adverse effects (such as digestive discomfort) have been identified, but the long-term safety profile and weight maintenance after cessation still require additional data. The enthusiasm surrounding this molecule is therefore scientifically grounded, positioning this compound as a major future pathway for weight management.

the sources

1. 1Wilding JPH et al. (STEP 1) 2021
2. 2Jastreboff AM et al. (SURMOUNT-1) 2022
3. 3Jastreboff AM et al. 2023
4. 4Wilding JPH et al. (STEP 1 extension) 2022